

A1
1. (Amended) A method for treating a human with a stimulant dependency, said method comprising administering to said human pramipexole in a dose ranging from 1.5 mg/day to 6.0 mg/day.

A2
4. (Amended) A method of treating a cocaine craving in a human, said method comprising administering to said human pramipexole in a dose ranging from 1.5 mg/day to 6.0 mg/day.

8. (New) The method of claim 1, wherein said pramipexole is administered in a dose ranging from 1.5 mg/day to 4.5 mg/day.

A3
9. (New) The method of claim 4, wherein said pramipexole is administered in a dose ranging from 1.5 mg/day to 4.5 mg/day.

10. (New) A method for treating a human with a stimulant dependency, said method comprising administering to said human a therapeutically effective amount of pramipexole and a therapeutically effective amount of an antidepressant.

11. (New) A method for treating a human with a stimulant dependency, said method comprising administering to said human a therapeutically effective amount of pramipexole and a therapeutically effective amount of an anticonvulsant.

12. (New) A method for treating a human with a cocaine craving dependency, said method comprising administering to said human a therapeutically effective amount of pramipexole and a therapeutically effective amount of an antidepressant.

13. (New) A method for treating a human with a cocaine craving in a human, said method comprising administering to said human a therapeutically effective amount of

pramipexole and a therapeutically effective amount of an anticonvulsant.

14. (New) The method of claim 11 or 13, wherein said anticonvulsant is lamotrigine.

15. (New) A method for treating a human with a stimulant dependency, said method comprising administering to said human pramipexole, wherein said pramipexole is administered intranasally.

16. (New) The method of claim 15, wherein said stimulant dependency involves a stimulant craving.

17. (New) The method of claim 16, wherein said stimulant is cocaine.

18. (New) A method of treating a cocaine craving in a human, said method comprising administering to said human pramipexole, wherein said pramipexole is administered intranasally.

19. (New) The method of claim 15 or 18, wherein said pramipexole is administered in a dose ranging from 1.5 mg/day to 6.0 mg/day.

20. (New) The method of claim 19, wherein said pramipexole is administered in a dose ranging from 1.5 mg/day to 4.5 mg/day.

21. (New) The method of claim 15 or 18, further comprising administering to said human a therapeutically effective amount of an antidepressant.

22. (New) The method of claim 15 or 18, further comprising administering to said human a therapeutically effective amount of an anticonvulsant.

AB

23. (New) The method of claim 22, wherein said anticonvulsant is lamotrigine.
